PE20170669A1 - Compuesto heterociclico - Google Patents

Compuesto heterociclico

Info

Publication number
PE20170669A1
PE20170669A1 PE2017000713A PE2017000713A PE20170669A1 PE 20170669 A1 PE20170669 A1 PE 20170669A1 PE 2017000713 A PE2017000713 A PE 2017000713A PE 2017000713 A PE2017000713 A PE 2017000713A PE 20170669 A1 PE20170669 A1 PE 20170669A1
Authority
PE
Peru
Prior art keywords
trifluoromethyl
bis
phenyl
ring
oxy
Prior art date
Application number
PE2017000713A
Other languages
English (en)
Inventor
Yoshihiro Banno
Masahiro Kamaura
Kazuaki Takami
Koichiro Fukuda
Shigekazu Sasaki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PE20170669A1 publication Critical patent/PE20170669A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/38—One oxygen atom attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Abstract

Se refiere a un compuesto de formula I, donde: el anillo A es un anillo pirazol, un anillo piridina o un anillo pirimidina; X es CH2 u O; y R es un atomo de hidrogeno o alquilo C1-C6. Son compuestos preferidos: acido ((2-(3,5-bis(trifluorometil)fenil)pirimidin-5-il)oxi)acetico; acido ((6-(3,5-bis(trifluorometil)fenil)piridin-3-il)oxi)acetico; acido 3-(3-(3,5-bis(trifluorometil)fenil)-1H-pirazol-1-il)propanoico; entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos poseen accion de reduccion sobre la proteina de union a retinol 4 (RBP4), siendo utiles en el tratamiento de la degeneracion macular relacionada con la edad, enfermedad de Stargardt, entre otras
PE2017000713A 2014-10-24 2015-10-22 Compuesto heterociclico PE20170669A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014217770 2014-10-24
PCT/JP2015/079782 WO2016063933A1 (ja) 2014-10-24 2015-10-22 複素環化合物

Publications (1)

Publication Number Publication Date
PE20170669A1 true PE20170669A1 (es) 2017-06-06

Family

ID=55760964

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000713A PE20170669A1 (es) 2014-10-24 2015-10-22 Compuesto heterociclico

Country Status (37)

Country Link
US (4) US10214498B2 (es)
EP (2) EP3210973B1 (es)
JP (2) JP6588027B2 (es)
KR (1) KR102490156B1 (es)
CN (2) CN115197160A (es)
AR (1) AR104342A1 (es)
AU (2) AU2015336480B2 (es)
BR (1) BR112017007138A2 (es)
CA (1) CA2965465C (es)
CL (1) CL2017000944A1 (es)
CO (1) CO2017003699A2 (es)
CR (1) CR20170160A (es)
CY (1) CY1123842T1 (es)
DK (1) DK3210973T3 (es)
DO (1) DOP2017000098A (es)
EA (1) EA033446B1 (es)
EC (1) ECSP17026687A (es)
ES (1) ES2848999T3 (es)
HR (1) HRP20210320T1 (es)
HU (1) HUE053443T2 (es)
IL (2) IL285105B2 (es)
LT (1) LT3210973T (es)
MA (2) MA39688B1 (es)
MX (2) MX2017004629A (es)
MY (1) MY183209A (es)
PE (1) PE20170669A1 (es)
PH (1) PH12017500747A1 (es)
PL (1) PL3210973T3 (es)
PT (1) PT3210973T (es)
RS (1) RS61504B1 (es)
SG (1) SG11201702312UA (es)
SI (1) SI3210973T1 (es)
TN (1) TN2017000097A1 (es)
TW (2) TWI703131B (es)
UA (1) UA121871C2 (es)
WO (1) WO2016063933A1 (es)
ZA (1) ZA201703344B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY183209A (en) 2014-10-24 2021-02-18 Takeda Pharmaceuticals Co Heterocyclic compound
AU2018240031B2 (en) 2017-03-20 2022-07-14 President And Fellows Of Harvard College Compounds and methods for the treatment of parasitic diseases
CN112512521A (zh) * 2018-08-01 2021-03-16 纽约市哥伦比亚大学理事会 用于治疗和预防非酒精性脂肪肝疾病和痛风的rbp4拮抗剂
CN111690698A (zh) * 2020-05-19 2020-09-22 浙江工业大学 两步串联流动合成3-（苯并[d][1,3]二氧-5-氨基）丙羟肟酸的方法
CN111690695A (zh) * 2020-05-19 2020-09-22 浙江工业大学 3-苯氨基丙羟肟酸的酶促微流控在线合成方法
WO2022256301A1 (en) * 2021-06-01 2022-12-08 Stargazer Pharmaceuticals, Inc. Methods and compounds for treating subjects with stargardt disease

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625970A (en) 1968-04-17 1971-12-07 Cutter Lab 1-(disubstituted phenyl or benzyl)-1h-indazol-3-yloxyacetic acid
US5239080A (en) 1989-02-08 1993-08-24 Takeda Chemical Industries, Ltd. Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents
EP0440183A1 (en) * 1990-02-01 1991-08-07 Takeda Chemical Industries, Ltd. Oxazole compounds, their production and use
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
WO1999022735A1 (en) 1997-10-30 1999-05-14 Merck & Co., Inc. Somatostatin agonists
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
WO2001025228A1 (fr) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Derives d'amines
MXPA02004647A (es) 1999-11-10 2002-10-31 Takeda Chemical Industries Ltd Compuestos heterociclicos de 5 miembros que contienen nitrogeno.
GB0020351D0 (en) 2000-08-17 2000-10-04 Catalyst Biomedica Ltd Treatment of hyperproliferative diseases
DE10149568A1 (de) * 2001-10-08 2003-04-24 Consequence Gmbh Verfahren zur Sequenzanalyse von Polypeptiden
WO2003042204A1 (fr) 2001-10-19 2003-05-22 Takeda Chemical Industries, Ltd. Derive d'amine
US20040214788A1 (en) 2003-03-11 2004-10-28 Raj Madhwa H.G. Treatment of prostate cancer
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
ES2278346T3 (es) 2003-08-20 2007-08-01 Eli Lilly And Company Compuestos, procedimientos y formulaciones para suministro oral de un compuesto peptido (glp)-1 del tipo de glucagon o un peptido agonista (glp)-4 del receptor 4 de melacortina (mc4).
JP4869942B2 (ja) 2003-12-11 2012-02-08 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド インスリン感受性／抵抗性、糖尿病および肥満におけるｒｂｐ４
US7838561B2 (en) 2004-06-14 2010-11-23 Wisconsin Alumni Research Foundation Method for preventing or treating cardiac hypertrophy
AU2005262558B8 (en) 2004-06-23 2008-04-10 Revision Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
JP2008507557A (ja) 2004-07-22 2008-03-13 ヴァンダ ファーマシューティカルズ インコーポレイテッド 眼疾患の治療法
US7947267B2 (en) 2004-10-08 2011-05-24 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
KR20090029814A (ko) 2006-06-22 2009-03-23 시리온 테라퓨틱스, 인크. 메갈린 활성의 조절을 통한 안질환의 치료 방법 및 조성물
AU2008268409B2 (en) 2007-06-26 2013-12-05 Lexicon Pharmaceuticals, Inc. Compositions comprising tryptophan hydroxylase inhibitors
BRPI0813212A2 (pt) 2007-06-26 2014-12-23 Lexicon Pharmaceuticals Inc Métodos de tratamento de doenças e distúrbios mediados por serotonina
WO2009042444A2 (en) 2007-09-27 2009-04-02 Sirion Therapeutics, Inc. Methods and compounds for treating retinol-related diseases
US7973079B2 (en) 2007-09-27 2011-07-05 Revision Therapeutics, Inc. Methods and compounds for treating retinol-related diseases
WO2009051244A1 (ja) 2007-10-18 2009-04-23 Takeda Pharmaceutical Company Limited 複素環化合物
US8541388B2 (en) 2008-05-22 2013-09-24 Isis Pharmaceuticals, Inc. Methods for modulating expression of RBP4
WO2009145286A1 (ja) * 2008-05-30 2009-12-03 武田薬品工業株式会社 複素環化合物
CA2758587A1 (en) 2009-04-13 2010-10-21 Irm Llc Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4)
AU2010237750A1 (en) * 2009-04-16 2011-11-17 Takeda Pharmaceutical Company Limited Derivatives of N-acyl-N'-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes
JP2013509430A (ja) 2009-10-28 2013-03-14 リヴィジョン セラピューティクス，インク． レチンアミドによる皮膚癌の予防
WO2011072275A2 (en) 2009-12-11 2011-06-16 Nono, Inc. Agents and methods for treating ischemic and other diseases
EP2560966B1 (en) 2010-03-30 2021-01-06 Verseon International Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
US8980924B2 (en) 2010-11-24 2015-03-17 The Trustees Of Columbia University In The City Of New York Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease
US9556166B2 (en) 2011-05-12 2017-01-31 Proteostasis Therapeutics, Inc. Proteostasis regulators
GB201205679D0 (en) 2012-03-30 2012-05-16 Dyson Technology Ltd A hand held appliance
WO2013166041A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular
WO2014134127A1 (en) 2013-02-26 2014-09-04 Northeastern University Cannabinergic nitrate esters and related analogs
WO2014160409A1 (en) 2013-03-14 2014-10-02 The Trustees Of Columbia University In The City Of New York Rbp4 antagonists for the treatment of age-related macular degeneration and stargardt disease
WO2014153643A1 (en) 2013-03-26 2014-10-02 The University Of British Columbia Compositions and methods for use thereof in the treatment of aniridia
AU2015226881A1 (en) 2014-03-07 2016-09-29 Intonation Research Laboratories Inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylases (HDACs)
EP3209656B1 (en) 2014-10-24 2020-04-01 Bristol-Myers Squibb Company Indole carboxamides compounds useful as kinase inhibitors
MY183209A (en) * 2014-10-24 2021-02-18 Takeda Pharmaceuticals Co Heterocyclic compound
SG10201903619YA (en) 2014-10-24 2019-05-30 Bristol Myers Squibb Co Carbazole derivatives
US11040976B2 (en) 2015-04-24 2021-06-22 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use

Also Published As

Publication number Publication date
PH12017500747B1 (en) 2017-10-30
IL251695A0 (en) 2017-06-29
AU2020204426B2 (en) 2022-02-03
CA2965465C (en) 2023-08-01
CN115197160A (zh) 2022-10-18
BR112017007138A2 (pt) 2017-12-26
TN2017000097A1 (en) 2018-07-04
IL285105A (en) 2021-08-31
EP3848353A1 (en) 2021-07-14
EP3210973A1 (en) 2017-08-30
WO2016063933A1 (ja) 2016-04-28
US20210340114A1 (en) 2021-11-04
PL3210973T3 (pl) 2021-06-28
CN107108506B (zh) 2022-06-21
IL285105B2 (en) 2023-03-01
MA53568A (fr) 2022-02-23
CN107108506A (zh) 2017-08-29
HUE053443T2 (hu) 2021-06-28
JPWO2016063933A1 (ja) 2017-08-03
DK3210973T3 (da) 2021-02-08
MX2017004629A (es) 2017-06-30
JP6995094B2 (ja) 2022-02-21
SI3210973T1 (sl) 2021-04-30
US20190119225A1 (en) 2019-04-25
CA2965465A1 (en) 2016-04-28
TWI749661B (zh) 2021-12-11
ES2848999T3 (es) 2021-08-13
EP3210973B1 (en) 2020-12-02
US20200157062A1 (en) 2020-05-21
CL2017000944A1 (es) 2018-01-12
TW201714876A (zh) 2017-05-01
DOP2017000098A (es) 2017-07-15
AU2015336480A2 (en) 2017-06-01
RS61504B1 (sr) 2021-03-31
CO2017003699A2 (es) 2017-07-28
US20180237404A1 (en) 2018-08-23
KR20170067791A (ko) 2017-06-16
PT3210973T (pt) 2021-02-12
EA201790912A1 (ru) 2017-09-29
MX2021001188A (es) 2021-04-19
IL285105B (en) 2022-11-01
AR104342A1 (es) 2017-07-12
AU2015336480B2 (en) 2020-04-02
UA121871C2 (uk) 2020-08-10
EP3210973A4 (en) 2018-04-25
US10544111B2 (en) 2020-01-28
KR102490156B1 (ko) 2023-01-18
TWI703131B (zh) 2020-09-01
ECSP17026687A (es) 2017-09-29
CR20170160A (es) 2017-06-15
MY183209A (en) 2021-02-18
TW202042805A (zh) 2020-12-01
IL251695B (en) 2021-08-31
LT3210973T (lt) 2021-03-25
MA39688B1 (fr) 2021-02-26
ZA201703344B (en) 2018-08-29
HRP20210320T1 (hr) 2021-04-30
JP6588027B2 (ja) 2019-10-09
AU2015336480A1 (en) 2017-05-25
MA39688A (fr) 2017-08-30
AU2020204426A1 (en) 2020-07-23
CY1123842T1 (el) 2022-05-27
SG11201702312UA (en) 2017-05-30
JP2020007347A (ja) 2020-01-16
EA033446B1 (ru) 2019-10-31
US10214498B2 (en) 2019-02-26
US10975043B2 (en) 2021-04-13
PH12017500747A1 (en) 2017-10-30

Similar Documents

Publication Publication Date Title
PE20170669A1 (es) Compuesto heterociclico
PE20161438A1 (es) Inhibidores de desmetilasa 1 especifica a lisina
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
PE20170677A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
MX2018005115A (es) Derivados de heterociclos biciclicos condensados como agentes de control de plagas.
PH12018500638A1 (en) 2-(het)aryl-substituted condensed bicyclic heterocyclic derivatives as pest control agents
PH12018500264A1 (en) 2-(het)aryl-substituted condensed heterocyclic derivatives as pest control agents
IN2014DN03063A (es)
JO3413B1 (ar) مشتقات نافثيريدين في صورة مضادات ألفا v بيتا 6 إنتيجرين لعلاج الأمراض الليفية e.g
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PH12015502038A1 (en) 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
EA201591908A1 (ru) Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CO6801777A2 (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
NZ627586A (en) Pyridone derivatives
EA201892415A1 (ru) Полиморфная форма n-{6-(2-гидроксипропан-2-ил)-2-[2-(метилсульфонил)этил]-2н-индазол-5-ил}-6-(трифторметил)пиридин-2-карбоксамида
NZ630124A (en) Estrogen receptor modulators and uses thereof
PE20091002A1 (es) Analogos dipeptidos como inhibidores del factor de coagulacion
PE20181288A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
PE20090984A1 (es) Inhibidores de peptido desformilasa
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
EA201691997A1 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
PE20161369A1 (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona sustituidos con tetrazolona